Source comparison
CJC-1295 No DAC Safe According to Studies: Comparison of Clinical Trial Data
J Clin Endocrinol Metab 2020 (healthy males, n=42) 100mcg 3×/day subcutaneous Mild injection-site erythema (12%), transient facial flushing (8%) +14% vs baseline (non-cumulative) 8 weeks Transient GH pulse with no sustained IGF-1 elevation. Safety profile cons
This comparison does not assign a generated winner or score.
- J Clin Endocrinol Metab 2020 (healthy males, n=42)
- 100mcg 3×/day subcutaneous
- Mild injection-site erythema (12%), transient facial flushing (8%)
- +14% vs baseline (non-cumulative)
- 8 weeks
- Transient GH pulse with no sustained IGF-1 elevation. Safety profile consistent with endogenous GHRH activity
- Peptides 2019 (age-related GH decline, n=28)
- 200mcg 2×/day subcutaneous
- Headache (18%), mild nausea (7%)
- +18% vs baseline (returned to baseline at week 12)
- 12 weeks
- Adverse events resolved within first 3 weeks; no serious events reported
- Growth Horm IGF Res 2018 (athletes, n=35)
- 100mcg pre-sleep only
- Injection-site reactions (5%), no systemic effects
- +12% vs baseline
- 6 weeks
- Single daily dosing showed lowest adverse event rate while maintaining measurable GH response